BioLife Solutions, Inc. filed a Form 8-K on September 9, 2026, reporting that the Hart-Scott-Rodino Antitrust Improvements Act waiting period applicable to its planned merger with Repligen Corporation expired at 11:59 p.m. Eastern Time on September 3, 2026.

Key Highlights

  • HSR waiting period expired: The required antitrust waiting period expired at 11:59 p.m. Eastern Time on September 3, 2026.
  • Merger consideration: BioLife stockholders are to receive $11.25 cash and 0.1442 shares of Repligen common stock per BioLife share, according to the filing.
  • Merger agreement date: BioLife and Repligen entered into the Agreement and Plan of Merger on July 21, 2026.
  • Stockholder vote scheduled: A special meeting of BioLife stockholders to consider adoption of the Merger Agreement is scheduled for October 5, 2026, at 9:00 a.m. Eastern Time, to be held by means of remote communication.
  • Two-step structure: The transaction is structured as two sequential mergers, with BioLife first surviving as a direct, wholly owned subsidiary of Repligen, then merging into Merger Sub 2.
  • Registration Statement effective: Repligen's Registration Statement on Form S-4, as amended, became effective on September 4, 2026, according to the filing.

BioLife-Repligen Merger Clears Key Antitrust Milestone

According to the Form 8-K filed with the SEC by BioLife Solutions, Inc. (NASDAQ:BLFS), the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period relating to the proposed acquisition of BioLife by Repligen Corporation expired at 11:59 p.m. Eastern Time on September 3, 2026. The filing notes this waiting period was a required condition to completing the mergers described in the Agreement and Plan of Merger entered into on July 21, 2026.

Under the terms of the Merger Agreement as disclosed, Repligen will acquire all outstanding shares of BioLife Common Stock, par value $0.001 per share, for $11.25 in cash and 0.1442 shares of Repligen common stock per share. The transaction is structured as two successive mergers: first, Merger Sub 1 merges with and into BioLife, with BioLife surviving as a direct, wholly owned subsidiary of Repligen; immediately thereafter, BioLife merges with and into Merger Sub 2, a Delaware limited liability company, which survives as a direct, wholly owned subsidiary of Repligen.

The filing states that completion of the mergers remains subject to other customary closing conditions, including adoption of the Merger Agreement by BioLife stockholders. The special stockholder meeting has been scheduled for October 5, 2026, at 9:00 a.m. Eastern Time, to be held by means of remote communication. The filing also notes that the Registration Statement on Form S-4 filed by Repligen became effective on September 4, 2026. The filing contains forward-looking statements, which the company identifies as subject to risks and uncertainties as described in its cautionary language.

What Was Disclosed

BioLife Solutions reported via this Form 8-K that the HSR antitrust waiting period for its planned acquisition by Repligen Corporation expired on September 3, 2026, removing one key regulatory condition while stockholder approval and other closing conditions remain pending.